Overview

Study to Evaluate Sotatercept (MK-7962) in Children With Pulmonary Arterial Hypertension (PAH) (MK-7962-008)

Status:
Not yet recruiting
Trial end date:
2028-09-21
Target enrollment:
Participant gender:
Summary
The primary objectives of the study are to evaluate the safety and tolerability, and pharmacokinetics (PK) of sotatercept over 24 weeks of treatment in children ≥1 to <18 years of age with PAH World Health Organization (WHO) Group 1 on standard of care (SoC). There is no formal hypothesis.
Phase:
Phase 2
Details
Lead Sponsor:
Merck Sharp & Dohme LLC